Beam Therapeutics CEO sells 30,078 shares in open-market transaction on April 1, 2026

By Robert Izquierdo – Apr 11, 2026 at 9:20AM EST Key Points - CEO John M. Evans sold 30,078 company shares for a transaction value of ~$739,000 on April 1, 2026. - The sale represented 2.5% of his direct holdings. - Only direct shares were disposed; indirect holdings (~103,000 shares via John M. Evans, III 2018 Irrevocable Trust) were unaffected. - This routine Rule 10b5-1 plan sale follows a cadence of smaller tranches as direct ownership has declined, with over $25.36 million in direct shares remaining post-transaction. John M. Evans, CEO of Beam Therapeutics ( BEAM ) (+4.18%), executed an open-market sale of 30,078 shares on April 1, 2026, valued at approximately $739,000 according to the SEC Form 4 filing. Transaction summary | Metric | Value | | --- | --- | | Shares sold (direct) | 30,078 | | Transaction value | ~$739,000 | | Post-transaction shares (direct) | 1,047,205 | | Post-transaction value (direct ownership) | $25.36 million | _Transaction value based on SEC Form 4 reported price ($24.58); post-transaction value based on April 1, 2026 market close ($24.22). Key questions * **How does the size of this sale compare to Evans' recent selling activity?** The 30,078 shares sold is below the reported mean for Evans' sell-only transactions (~45,200 shares) and marks the smallest open-market sale in the last four disclosed sales, aligning with a declining direct share base. * **What is the impact of this sale on insider ownership and alignment?** After the transaction, Evans retains 1,047,205 direct shares and 103,000 indirect shares, with direct insider ownership now representing 1.03% of outstanding shares, sustaining a material equity interest. * **What was the price context for this transaction, and did it reflect a premium or discount to recent trading?** The shares were sold at around $24.58 per share, which was slightly above the April 1, 2026 closing price of $24.22 but below the closing price of $27.43 as of April 10, 2026. * **Does this transaction suggest a change in selling cadence or strategy?** The sale was executed under a pre-established Rule 10b5-1 trading plan, and the decrease in sale size is consistent with reduced direct share capacity from prior transactions rather than a shift in portfolio strategy. Company overview | Metric | Value | | --- | --- | | Price (as of market close April 1, 2026) | $24.22 | | Market capitalization | $2.79 billion | | Revenue (TTM) | $139.74 million | | 1-year price change | 60.84% | Beam Therapeutics develops precision genetic medicines, including base editing therapies for sickle cell disease, beta thalassemia, T-cell acute lymphoblastic leukemia, and metabolic and rare genetic disorders. It has established multiple research collaborations and licensing agreements with pharmaceutical and biotechnology partners. The company targets patients with serious genetic diseases, with a focus on rare disease populations and partnerships with leading healthcare organizations. Beam Therapeutics is a clinical-stage biotechnology company specializing in the development of precision genetic medicines using base editing technology. The company's strategy centers on advancing a diversified pipeline of therapeutic candidates for hematologic, liver, and rare genetic disorders, leveraging collaborations with major industry players. With a focus on innovation and strategic partnerships, Beam aims to address high unmet medical needs in the genetic medicine landscape. What this transaction means for investors Beam Therapeutics CEO John Evans’ April 1 sale of 30,078 company shares is not a warning sign for investors. The stock was sold to cover tax withholding obligations in connection with the vesting of restricted stock units. The transaction comes at a time when Beam Therapeutics stock surged due to positive clinical data related to its ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) treatment for sickle cell disease. The company exited 2025 with revenue of $139.7 million, up from 2024’s $63.5 million. However, its 2025 research and development costs increased year over year to $409.6 million, resulting in a loss from operations of $383.7 million. Even so, this is a reduction compared to 2024’s operating loss of $415.6 million, which is an encouraging sign. Moreover, the company ended 2025 with $1.2 billion in cash and marketable securities. This provides a robust sum to maintain operations as it progresses development of its treatments.